CN101347469A

CN101347469A - Composition containing extracts of Butyrospermum parkii and the use as medicament or dietary supplement

Info

Publication number: CN101347469A
Application number: CNA2008101336438A
Authority: CN
Inventors: M·S·温德纳
Original assignee: BSP Pharma AS
Current assignee: BSP Pharma AS
Priority date: 1999-07-09
Filing date: 2000-07-10
Publication date: 2009-01-21

Abstract

The present invention relates to a composition comprising an extract or a concentrate of Butyrospermum parkii as a dietary supplement or a pharmaceutical composition and to the use of such compositions for the preparation of a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction. The composition may optionally be formulated with a pharmaceutically acceptable carrier for systemic or topical administration. More specifically, the invention relates to a dietary supplement or a pharmaceutical composition comprising an extract or a concentrate of Butyrospermum parkii, wherein said extract or concentrate contains Butyrospermum-triterpenes and optionally the sterols stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and alpha-spinasterol.

Description

Contain the compositions of extracts of Butyrospermum parkii and as the purposes of medicine or food supplement

The application is to be that July 10, application number in 2000 are 00811168.5 (PCT/DK00/00383) applying date, and denomination of invention is divided an application for the Chinese patent application of " contain the compositions of extracts of Butyrospermum parkii and as the purposes of medicine or food supplement ".

Technical field

The present invention relates to be used for the food supplement or the pharmaceutical composition of whole body or topical, it comprises extracts of Butyrospermum parkii or the concentrate of preparing with the pharmaceutically suitable carrier that is used for whole body or topical alternatively.More particularly, the present invention relates to comprise the food supplement or the pharmaceutical composition of extracts of Butyrospermum parkii or concentrate, wherein said extract or concentrate contain triterpene alcohol butyryl spermol, lupeol, parkeol, germanicol,

Agate dienol, 24-methylene-

Agate enol, α-Zhi Tansu and β-fat wingceltis are plain and contains sterol stigmasterol, avenasterol (avanasterol), 24-methyl-cholest-7-enol, candle fruit sterol A (karitesterol A), candle fruit sterol B and hitodesterol alternatively, and this based composition is used for suppressing the purposes of the medicine or the food supplement of allergy and/or inflammatory reaction in preparation.

Background technology

Allergy is defined as a kind of reactivity behaviour of change, and wherein health excessive immune response occurs to material (antigen).Allergy may be caused by external source or endogenic antigen.

Anaphylaxis is the basis of a large amount of diseases.Wherein the most important thing is allergia and autoimmune disease.Textbook " clinical medicine " (Kumar, P. and Clark, M.: " clinical medicine ", the 3rd edition, the 147-150 page or leaf, 1994, Bailliere Tindall provided the classification of anaphylactic disease in London).

Type i allergic reaction (IgE mediation allergy) causes by allergen (specificity exogenous antigen), for example pollen, indoor dust, animal scurf, mycete etc.Wherein the allergic disease that plays an important role of I type reaction comprises asthma, eczema (atopic dermatitis), urticaria, allergic rhinitis and anaphylaxis.

The anaphylaxis of II type is caused by cell surface or tissue bond antibody (IgG and IgM), and plays an important role in the pathogeny of myasthenia gravis, Goodpasture's syndrome and Addison's anemia etc.

III type anaphylaxis (immunity is compound) is caused by autoantigen or exogenous antigen, such as some antibacterial, fungus and parasite.Wherein the disease that plays a major role of III type anaphylaxis comprises lupus erythematosus, rheumatoid arthritis and glomerulonephritis.

Type iv allergic reaction (delayed) is caused by the cell or tissue conjugated antigen.Such anaphylaxis plays an important role in many sufferers, for example graft versus host disease, leprosy, contact dermatitis and the reaction that causes because of insect bite.

There are many class medicines to can be used for treating anaphylaxis.Wherein corticosteroid be to use a class medicine the most widely.Corticosteroid mainly causes their pharmacotoxicological effect is brought into play in anaphylactoid inhibition thus by function and the propagation that non-selectively suppresses various different types of immunocytes.Unfortunately, corticosteroid has many serious adverse, for example immunosuppressant, osteoporosis and atrophoderma.

Africa trees sheas (Butyrospermum pakii), the fruit tree (karite tree) that is referred to as usually to light up, grows wild is in the dry area of Central Africa, equator.The fruit of this tree comprises a kind of nut, is referred to as Butyrospermum nut (shea nut) usually.The long 3-4cm of this nut, oil content is about 50%.Main body of oil is a triglyceride, but should oil also contains the not saponification composition of being made up of polyisoprene hydrocarbon (karitene), triterpene alcohol and sterol of several percentage ratios.This oil generally is referred to as Adeps Bovis seu Bubali resin.The feature triterpene alcohol of Butyrospermum parkii (being called shea-triterpene in the present invention) be lupeol, parkeol, germanicol,

Agate dienol, 24-methylene-

Agate enol, butyryl spermol, α-Zhi Tansu and β-fat wingceltis element, and ester, esp meat cinnamic acid, acetic acid or fatty acid ester.

Usually Adeps Bovis seu Bubali resin contains shea-triterpene of 1-5% (w/w), and the dosage of Adeps Bovis seu Bubali resin in existing local beauty or drug products is 1-20% (w/w), and the senior general of the content of shea-triterpene in this series products is 1% (w/w).

FR 2770400 (WO 99/22706) discloses beauty treatment or the dermatological department pharmaceutical composition that contains the Butyrospermum parkii flower extract.This patent does not describe colored chemical constituent in detail, but according to known to the inventor, flower does not contain the shea-triterpene of any real mass.

Adeps Bovis seu Bubali resin is widely used as emollient in cosmetics, be used as the mutually fatty of topical drug's product such as ointment and cream cream on less degree.

GB 932662 discloses the pharmaceutical composition that comprises the butyryl spermol.According to this patent, the butyryl spermol can obtain from Butyrospermum parkii.

Known to the inventor, what describe in further detail hereinafter never disclosed in the past in the literature according to the pharmaceutical composition that contains extracts of Butyrospermum parkii or concentrate of the present invention.

Summary of the invention

The inventor finds, the compositions that comprises extracts of Butyrospermum parkii or concentrate has significantly suppressed anaphylaxis when the whole body administration, wherein said extract or concentrate comprise shea-triterpene composition of at least 5%, and described triterpene is selected from the following member: butyryl spermol, lupeol, Parker alcohol (parkeol), germanicol,

Agate dienol, 24-methylene-

Agate enol, α-Zhi Tansu and β-fat wingceltis element, and the optional at least a sterol that is selected from the following member: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol, wherein said shea-triterpene and sterol can be the forms of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester.Alternatively, described extract or concentrate comprise the pharmaceutically suitable carrier that is used for the whole body administration.

In addition, the inventor finds that the pharmaceutical composition that comprises at least 5% shea-triterpene and optional pharmaceutically suitable carrier has significantly suppressed the inflammation or the anaphylaxis of skin or mucosa when local the application.This is surprising, because these effects are used up to now by Adeps Bovis seu Bubali resin can't be obtained as shea-triterpene that emollient is used for the low concentration of topical remedy or cosmetics.

In addition, the inventor finds that also the pharmaceutical composition that contains the conjugate of at least 5% shea-triterpene and Flos Inulae extract has useful especially pharmacology's performance.

Compare with existing therapeutic agent such as corticosteroid or non-steroidal anti-inflammatory drug, pharmaceutical composition of the present invention and food supplement have the advantage of any serious side effects of unlikely generation, because their all the components all is nontoxic under pharmacology's relevant dose and can be well tolerable by organism.

Because can being used for following treatment, the top pharmacotoxicological effect of mentioning, pharmaceutical composition of the present invention and food supplement use:

Immunomodulating.

Treatment or Polyglucan disease.

Treatment or prevention scytitis or allergy.

Treatment or prevention mucosal inflammation or allergy.

The allergy and the patient's condition of treatment or prevention IgE mediation.

Treatment or prevention autoimmune disease.

Ease the pain.

Therefore, the invention provides a kind of food supplement or pharmaceutical composition, it comprises:

1, extracts of Butyrospermum parkii or concentrate, described extract or concentrate comprise shea-triterpene composition of at least 5%, and described triterpene is selected from the following member: butyryl spermol, lupeol, Parker alcohol, germanicol,

Agate dienol, 24-methylene-

Agate enol, α-Zhi Tansu and β-fat wingceltis element; Optionally

2, at least a sterol that is selected from the following member: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol, wherein said triterpene and sterol can be the forms of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester; Optionally

3, pharmaceutically suitable carrier, described carrier or be suitable for the whole body administration or be suitable for topical.

Described pharmaceutical composition goes for the whole body administration, perhaps is applicable to skin or mucosa topical.

In addition, the compositions that is used for the whole body administration that the invention provides the pharmaceutically suitable carrier that comprises aforesaid extracts of Butyrospermum parkii or concentrate and optionally be used for the whole body administration is used for mammiferous immunomodulating in preparation, is used to the purposes that suppresses the allergy and the mammiferous autoimmune response of mammiferous anaphylaxis such as IgE mediation and be used to alleviate the medicine of mammiferous pain.

Therefore, according to the present invention, be used for comprising of whole body administration aforesaid extracts of Butyrospermum parkii or concentrate and the compositions that optionally is used for pharmaceutically suitable carrier of whole body administration can be used for the treatment of or prevent the method for mammiferous anaphylactic disease to use, described method comprises the described compositions of described mammal administration; And the present invention includes described compositions is used for the treatment of or prevents purposes in the medicine of mammal anaphylactic disease in preparation.

And, according to the present invention, be used for comprising of whole body administration aforesaid extracts of Butyrospermum parkii or concentrate and the compositions that optionally is used for pharmaceutically suitable carrier of whole body administration can be used for the treatment of or prevent the method for mammiferous autoimmune disease to use, described method comprises the described compositions of described mammal administration; And the present invention includes described compositions is used for the treatment of or prevents purposes in the medicine of mammal autoimmune disease in preparation.

In addition, according to the present invention, be used for comprising of whole body administration aforesaid extracts of Butyrospermum parkii or concentrate and the compositions that optionally is used for pharmaceutically suitable carrier of whole body administration can be used for the treatment of or prevent the allergy of mammiferous IgE mediation or the method for sufferer to use, described method comprises the described compositions of described mammal administration; And the present invention includes described compositions is used for the treatment of or prevents purposes in the medicine of the allergy of mammiferous IgE mediation and sufferer in preparation.

And, according to the present invention, be used for comprising of whole body administration aforesaid extracts of Butyrospermum parkii or concentrate and the compositions that optionally is used for pharmaceutically suitable carrier of whole body administration can use in the method that is used to alleviate mammal pain, described method comprises the described compositions of described mammal administration; And the present invention includes described compositions is used for alleviating the medicine of mammiferous pain in preparation purposes.

In addition, the invention provides a kind of pharmaceutical composition, it comprises: i) at least 5% (w/w) shea-triterpene; Ii) Flos Inulae extract; Optional iii) pharmaceutically suitable carrier.Be preferred for skin or mucosa topical.

Therefore, the invention provides the pharmaceutical composition that contains at least 5% shea-triterpene, wherein this pharmaceutical composition is mixed with liquid, ointment, gel, liniment, Emulsion (for example cream frost or honeydew) or spray (for example aerosol).

According to the present invention, comprise at least 5% shea-triterpene and optionally the pharmaceutical composition of pharmaceutically suitable carrier can use in mammalian skin or mucosal inflammation or the hypersensitive method being used for the treatment of or preventing, described method comprises the described compositions of described mammal topical; And the present invention includes described compositions is used for the treatment of or prevents purposes in mammalian skin or mucosal inflammation or the hypersensitive medicine in preparation.

And, according to the present invention, comprise at least 5% shea-triterpene and optionally the pharmaceutical composition of pharmaceutically suitable carrier can use in the method for mammiferous atopic dermatitis, psoriasis or contact dermatitis being used for the treatment of or preventing, described method comprises the described compositions of described mammal administration; And the present invention includes described compositions is used for the treatment of or prevents purposes in the medicine of mammiferous atopic dermatitis, psoriasis or contact dermatitis in preparation.

Detailed Description Of The Invention

The inventor has found a kind of food supplement or pharmaceutical composition significantly inflammation-inhibiting or anaphylaxis, and wherein said food supplement or pharmaceutical composition comprise:

1, extracts of Butyrospermum parkii or concentrate, described extract or concentrate comprise shea-triterpene composition of at least 5%, and described triterpene is selected from the following member: butyryl spermol, lupeol, Parker alcohol, germanicol, Agate dienol, 24-methylene-

Agate enol, α-Zhi Tansu and β-fat wingceltis element; Optionally

In embodiment 1, detect the antiinflammatory action of the present composition with mice anaphylaxis (arthritis) model of determining.In this experiment, the present composition has produced the remarkable effect (with 50mg/kg) that can be comparable to cyclophosphamide (with 10mg/kg).In one is independently tested (referring to embodiment 4), the identical present composition is to the LD of rat ₅₀Demonstration is greater than 2000mg/kg, and cyclophosphamide is to the LD of rat ₅₀Be 94mg/kg (" Merck index " the 13rd edition,, Merck﹠amp in 1989; Co Inc.).Therefore, the therapeutic index of the present composition is far superior to the therapeutic index of cyclophosphamide.

When used the part, this pharmaceutical composition had suppressed the inflammation or the anaphylaxis of skin or mucosa.

In embodiment 2, the local anti-inflammatory effect of different components of the present invention and the effect that contains the general compositions (contrast) of the Adeps Bovis seu Bubali resin that is equivalent to 2% shea-triterpene are compared.The present composition dose dependent ground that contains 10-30% shea-triterpene has suppressed the scytitis of mice, and contrast does not have antiinflammatory action.This is surprising, because these effects are used up to now by Adeps Bovis seu Bubali resin can't be obtained as shea-triterpene that emollient is used for the low concentration of topical remedy or cosmetics.

The present composition that is used for part or whole body administration provides beat all good antiallergic and antiinflammatory action and wonderful good security performance.Therefore, the present composition is actual nontoxic, but treatment is upward very effective.The inventor has proposed such hypothesis: the therapeutic index that is highly profitable that the present composition can be compared with single chemical Claritin is the more complicated characteristic of the present composition due to, be carried in toxicity on the health owing to the synergism between each composition of compositions has reduced any unification compound, produced astonishing excellent curative simultaneously again.

More particularly, the invention described above compositions provides following pharmacotoxicological effect after to the live organism administration:

The immunity modulation.

Suppress anaphylaxis.

Suppress scytitis or allergy.This effect can see any dermatosis or any disease that causes this skin symptom, such as atopic dermatitis, psoriasis, contact dermatitis or infectious disease.

Suppress mucosal inflammation or allergy.This effect can see any and mucosa diseases associated or any disease of this mucosal symptoms that causes comprises infectious disease.

The allergy that suppresses the IgE mediation.

Suppression of autoimmune responses.

Reduce pain.

Therefore, the invention provides a kind of pharmaceutical composition or food supplement, it comprises:

1) contain the extracts of Butyrospermum parkii or the concentrate of at least 5% (w/w) shea-triterpene composition, described shea-triterpene composition comprises:

-at least 2% (w/w) lupeol;

-at least 2% (w/w) α-Zhi Tansu and/or β-fat wingceltis element;

-at least 2% (w/w) butyryl spermol; With

-optionally at least 1% germanicol,

Agate dienol, 24-methylene- Agate enol and/or Parker alcohol,

Wherein said triterpene can be the form of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester; With

2) optional pharmaceutically suitable carrier.

Therefore, the invention provides a kind of pharmaceutical composition or food supplement, wherein the percetage by weight (w/w) of shea-triterpene composition in said composition is generally at least 5%, for example at least 6%, at least 7%, at least 8%, such as at least 9%, as at least 10%, such as at least 15%, as at least 20%, such as at least 25%, or at least 30%, as at least 35%, for example at least 40%, at least 45%, or at least 50%, such as at least 55%, for example at least 60%, as at least 65%, for example at least 70%, at least 75%, such as at least 80%, as at least 85%, such as at least 90%, as at least 95%, or at least 96%, such as at least 97%, as at least 98%, such as at least 99%, for example at least 100%; In addition, the percetage by weight (w/w) of shea-triterpene composition in said composition is generally at the most 100%, and for example 99%, at the most 98%, as at the most 97%, for example at the most 96%, as at the most 95%, as at the most 90%, as at the most 85%, as at the most 80%, as at the most 75%, as at the most 70%, at the most 65%, for example at the most 60%, as at the most 55%, as at the most 50%, as at the most 45%, at the most 40%, as at the most 35%, as at the most 30%, as at the most 25%, as at the most 20%, as at the most 15%, for example at the most 10%, for example at the most 9%, as at the most 8%, as at the most 7%, as at the most 6%, as at the most 5%; The percetage by weight (w/w) of shea-triterpene composition in said composition generally can be in the 5-100% scope, such as in the 6-98% scope, such as in the 7-96% scope, for example in the 8-94% scope, such as in the 9-92% scope, such as in the 10-90% scope, as in the 12-88% scope, for example in the 14-86% scope, such as in the 16-84% scope, such as in the 18-82% scope, for example in the 20-80% scope

Wherein shea-triterpene composition is made up of following material:

The lupeol of-at least 2% (w/w), for example at least 3%, such as at least 4%, for example at least 5%, for example at least 6%, at least 7%, at least 8%, such as at least 9%, as at least 10%, such as at least 15%, for example at least 20%, such as at least 25%, or at least 30%, for example at least 35%, for example at least 40%, at least 45%, or at least 50%, such as at least 55%, for example at least 60%, such as at least 65%, for example at least 70%, at least 75%, such as at least 80%, as at least 85%, such as at least 90%, as at least 95%, or at least 96%, such as at least 97%, as at least 98%, such as at least 99%, as at least 100%;

The α-Zhi Tansu of-at least 2% (w/w) and/or β-fat wingceltis element, for example at least 3%, such as at least 4%, for example at least 5%, as at least 6%, at least 7%, at least 8%, such as at least 9%, for example at least 10%, such as at least 15%, for example at least 20%, such as at least 25%, or at least 30%, for example at least 35%, as at least 40%, at least 45%, or at least 50%, such as at least 55%, for example at least 60%, such as at least 65%, for example at least 70%, at least 75%, such as at least 80%, as at least 85%, such as at least 90%, as at least 95%, or at least 96%, such as at least 97%, for example at least 98%, such as at least 99%, for example at least 100%;

The butyryl spermol of-at least 2% (w/w), for example at least 3%, such as at least 4%, for example at least 5%, as at least 6%, at least 7%, at least 8%, such as at least 9%, for example at least 10%, such as at least 15%, for example at least 20%, such as at least 25%, or at least 30%, for example at least 35%, as at least 40%, at least 45%, or at least 50%, such as at least 55%, for example at least 60%, such as at least 65%, for example at least 70%, at least 75%, such as at least 80%, as at least 85%, such as at least 90%, as at least 95%, or at least 96%, such as at least 97%, for example at least 98%, such as at least 99%, for example at least 100%;

-and optionally at least 1% (w/w) germanicol,

Agate dienol, 24-methylene-

Agate enol and/or Parker alcohol, for example at least 2%, for example at least 3%, such as at least 4%, for example at least 5%, as at least 6%, at least 7%, at least 8%, such as at least 9%, for example at least 10%, such as at least 15%, for example at least 20%, such as at least 25%, or at least 30%, for example at least 35%, as at least 40%, at least 45%, or at least 50%, such as at least 55%, for example at least 60%, such as at least 65%, for example at least 70%, at least 75%, such as at least 80%, as at least 85%, such as at least 90%, as at least 95%, or at least 96%, such as at least 97%, for example at least 98%, such as at least 99%, for example at least 100%.

In addition, the invention provides a kind of pharmaceutical composition or food supplement, it comprises:

A kind of pharmaceutical composition or food supplement that comprises following component:

-10-40% (w/w) lupeol;

-10-40% (w/w) α-Zhi Tansu and/or β-fat wingceltis element;

-10-40% (w/w) butyryl spermol; With

-optional 1-30% germanicol,

Agate dienol, 24-methylene- Agate enol and/or Parker alcohol,

Wherein said triterpene can be the form of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester; And shea-triterpene

Therefore, the invention provides a kind of pharmaceutical composition or food supplement, wherein the percetage by weight (w/w) of shea-triterpene lupeol in said composition generally can be in the 2-95% scope, such as in the 3-95% scope, such as in the 4-90% scope, for example in the 5-90% scope, such as in the 5-80% scope, such as in the 5-75% scope, for example in the 5-70% scope, as in the 5-65% scope, such as in the 5-60% scope, such as in the 5-55% scope, for example in the 5-50% scope, such as in the 6-45% scope, such as in the 7-40% scope, such as in the 8-40% scope, such as in the 9-40% scope, such as in the 10-40% scope; The percetage by weight (w/w) of shea-triterpene α-Zhi Tansu and/or β-fat wingceltis element in said composition usually can be in the 2-95% scope, such as in the 3-95% scope, such as in the 4-90% scope, for example in the 5-90% scope, such as in the 5-80% scope, such as in the 5-75% scope, for example in the 5-70% scope, as in the 5-65% scope, such as in the 5-60% scope, such as in the 5-55% scope, for example in the 5-50% scope, such as in the 6-45% scope, such as in the 7-40% scope, such as in the 8-40% scope, such as in the 9-40% scope, such as in the 10-40% scope; The percetage by weight (w/w) of shea-triterpene butyryl spermol in said composition usually can be in the 2-95% scope, such as in the 3-95% scope, such as in the 4-90% scope, for example in the 5-90% scope, such as in the 5-80% scope, such as in the 5-75% scope, for example in the 5-70% scope, as in the 5-65% scope, such as in the 5-60% scope, such as in the 5-55% scope, for example in the 5-50% scope, such as in the 6-45% scope, such as in the 7-40% scope, such as in the 8-40% scope, such as in the 9-40% scope, such as in the 10-40% scope; And alternatively, shea-triterpene germanicol,

Agate dienol, 24-methylene-

Agate enol and/or the Parker alcohol percetage by weight (w/w) in said composition usually can be in the 1-95% scope, such as in the 1-90% scope, such as in the 1-80% scope, for example in the 1-70% scope, such as in the 1-60% scope, such as in the 2-50% scope, for example in the 2-40% scope, as in the 2-35% scope, such as in the 2-30% scope.

In addition, the invention provides the pharmaceutical composition that is particularly suited for topical, it comprises: the i) shea of at least 5% (w/w)-triterpene composition; Ii) optional sterol composition; With the pharmaceutically suitable carrier that optionally iii) is used for topical, wherein shea-triterpene composition is generally at least 1% with the percetage by weight (w/w) of sterol composition in said composition alternatively, and for example at least 5%, at least 10%, at least 15%, such as at least 20%, as at least 25%, for example at least 30%, for example at least 35%, such as at least 40%, or at least 45%, for example at least 50%, for example at least 55%, at least 60%, or at least 65%, such as at least 70%, as at least 75%, for example at least 80%, for example at least 85%, at least 90%, such as at least 91%, as at least 92%, for example at least 93%, as at least 94%, at least 95%, or at least 96%, for example at least 97%, for example at least 98%, such as at least 99%, for example at least 100%; In addition, shea-triterpene composition is generally at the most 100% with the percetage by weight (w/w) of sterol composition in said composition alternatively, and for example 99%, at the most 98%, as at the most 97%, for example at the most 96%, as at the most 95%, as at the most 90%, as at the most 85%, as at the most 80%, as at the most 75%, as at the most 70%, at the most 65%, for example at the most 60%, as at the most 55%, as at the most 50%, as at the most 45%, at the most 40%, as at the most 35%, as at the most 30%, as at the most 25%, as at the most 20%, as at the most 15%, for example at the most 10%, for example at the most 9%, as at the most 8%, as at the most 7%, as at the most 6%, as at the most 5%; For example at the most 4%; For example at the most 3%; For example at the most 2%; For example at the most 1%; Shea-triterpene composition alternatively generally can be in the 1-100% scope with the percetage by weight (w/w) of sterol composition in said composition, such as in the 2-100% scope, such as in the 3-95% scope, for example in the 4-90% scope, such as in the 5-80% scope, such as in the 6-75% scope, as in the 7-70% scope, for example in the 8-65% scope, such as in the 9-60% scope, such as in the 10-55% scope, for example in the 10-50% scope, such as in the 10-45% scope, such as in the 10-40% scope.

Ratio between shea-triterpene and the sterol (shea-triterpene: sterol) 1: 100-500: in 1 scope, for example 1: 75-400: 1, such as 1: 50-300: 1, such as 1: 25-200: 1, preferred 1: 20-100: 1, for example 1: 10-75: 1, such as 1: 5-50: 1, more preferably 1: 4-25: in 1 scope, for example 1: 3-20: 1, such as 1: 2-19: 1, for example 1: 1-18: 1, for example 2: 1-17: 1, such as 3: 1-16: 1, first-selected 4: 1-15: 1, such as 5: 1-14: 1, for example 10: 1-13: 1; With

Triterpene alcohol and the sterol overall weight percent (w/w) in said composition is generally at least 0.005%, and for example at least 0.01%, at least 0.025%, at least 0.05%, or at least 0.075%, for example at least 0.1%, for example at least 0.25%, at least 0.5%, or at least 1.0%, for example at least 2.0%, for example at least 5.0%, at least 10.0%, at least 20.0%, at least 30.0% or at least 50.0%.

In the present invention, " shea-triterpene composition " is defined as the composition of the triterpene that comprises at least a following member of being selected from: lupeol, Parker alcohol, germanicol,

Agate dienol, 24-methylene-

Agate enol, butyryl spermol, α-Zhi Tansu and β-fat wingceltis element, and ester, esp meat cinnamic acid or acetas.The present composition can contain one or more in the above-mentioned triterpene, such as contain 2,3,4,5,6,7 kind or all above-listed shea-triterpenes, and/or 1,2,3,4,5,6,7 or 8 kind of its ester, esp meat cinnamic acid, acetic acid or fatty acid ester, and the mixture that comprises triterpene and ester.

" sterol composition " is defined as the composition of the sterol that comprises at least a following member of being selected from: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol.Compositions can contain one or more in the above-mentioned sterol, such as contain 2,3,4,5,6,7 kind or all above-listed sterols, wherein said sterol can be the form of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester.

Extracts of Butyrospermum parkii or concentrate can be from any positions of this plant, obtain such as fruit (nut), leaf, stem, bark or root.Preferred extract of the present invention or concentrate derive from fruit.In addition, extract of the present invention or concentrate can from derive from the Butyrospermum parkii fruit oil or fat (Adeps Bovis seu Bubali resin), for example comprise unsaponifiable fraction, obtain by any extraction or fractional method.Preferably, triterpene alcohol of the present invention and sterol obtain from oil or the fatty unsaponifiable fraction that derives from Butyrospermum parkii.

Extract of the present invention or concentrate can be for example by extracting or distillation (for example water, steam or vacuum distilling) fresh or exsiccant Butyrospermum parkii or its certain part, preferred nut part obtain.Extraction can be carried out with many different organic solvents.Extraction can adopt any extractive technique, for example dipping, percolation or supercritical extraction (for example using carbon dioxide) etc. to carry out under hot or cold condition.

Preferred extraction solvent is acetone, butanone, methyl acetate, ethyl acetate, the low-level chain triacontanol that contains 1-4 carbon atom, pentane, hexane, heptane and composition thereof.Consider extraction efficiency, preferably extract temperature near the boiling point of solvent for use, but also can adopt lower temperature that need longer extraction time this moment.

By changing the composition of solvent for use, can have more some component of optionally extracting Butyrospermum parkii, increase or reduce its content in final extract or concentrate thus.

Through behind the preliminary leaching process, can carry out the processing of second step, such as the distillation of liquid-liquid extraction, column chromatography or any kind, to remove or any component of concentrated extract.Can make any component of Butyrospermum parkii avoid appearing in the final extract thus or it is concentrated.Obtain compositions of the present invention so can make any components contents standardization, and the ratio in pharmaceutical composition of the present invention between different shea-triterpenes can be significantly different, under specific circumstances, can from particular composition of the present invention, get rid of any shea-triterpene and any amount of shea-triterpene.So shea-triterpene single probably or any other quantity constitutes the shea-triterpene composition of the present composition.

" food supplement " (DSHEA) defines 1994 " food supplement health and education regulations " according to food and drug administration.

DSHEA has provided the formal definition of following " food supplement ":

" food supplement:

Be intended to be used for replenish the product that has or contain one or more following composition of food (except Nicotiana tabacum L.) of diet: vitamin, mineral, medical herbs or other plant medical material, aminoacid, be used for the people with by increasing the edible material from soybeans that total daily intake replenishes diet, or the concentrate of these materials, metabolite, formation thing, extract or conjugate.

Be intended for use in ingesting with pill, capsule, tablet or liquid form.”

Other places in the world, for example similar definition arranged in Europe." food supplement " there are many different calls all over the world, such as " food supplement ", " no drugs with function (nentracentical) ", " functional food " or just be called " food " simply.In this article, term " food supplement " comprises any such title or definition.

" whole body administration " is defined as by the parenteral administration, such as by in the intravenous, intraperitoneal, intraarticular, ventricle, in the capsule, in the spinal column, intramuscular, subcutaneous, intradermal, oral cavity, cheek, Sublingual, nose, rectum, vagina or percutaneous approach.

The top pharmacotoxicological effect of mentioning is used for the following treatment of compositions that comprises aforesaid extracts of Butyrospermum parkii or concentrate and optionally be used for pharmaceutically suitable carrier of whole body administration the part principle is provided:

With the administration above-mentioned composition is the treatment of feature or the method for Polyglucan disease or inflammation.This therapeutical effect may with the disease association of all known and anaphylaxiss or inflammation-related.The allergy of autoimmune disease and IgE mediation has been made more detailed description below.Except these particular treatment scopes, the effect of above-mentioned composition and all known sufferer and the disease association relevant with anaphylaxis below are the limiting examples about this: infect (virus, antibacterial, fungus, parasite etc.), flu and influenza, contact dermatitis, sting, allergia nodular vasculitis, postoperative reaction, transplant rejection (graft versus host disease) etc.

With the administration above-mentioned composition is the treatment of feature or the method for prevention autoimmune disease.The applicant has proposed such hypothesis: this therapeutical effect should be given the credit to above-mentioned composition to anaphylactoid immunity modulation and inhibitory action.This therapeutical effect can relate to all known autoimmune diseases, below is the limiting examples about this: autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hemolytic anemia, exophthalmic goiter, myasthenia gravis, type 1 diabetes, inflammatory myopathy, multiple sclerosis, struma lymphomatosa, autoimmune adrenalitis, Crohn disease, ulcerative colitis, glomerulonephritis, progressive systemic sclerosis (scleroderma), sjogren disease, lupus erythematosus, the constitutional nodular vasculitis, rheumatoid arthritis, juvenile arthritis,juvenile chronic arthritis,juvenile rheumatoid arthritis, MCT's disease, psoriasis, pemphigus, pemphigoid, dermatitis herpetiformis etc.

With the administration above-mentioned composition is treatment or the allergy of prevention IgE mediation or the method for sufferer of feature.The applicant has proposed such hypothesis: this therapeutical effect is given the credit to above-mentioned composition to anaphylactoid inhibitory action.This therapeutical effect can relate to the allergy and the sufferer of all known IgE mediations, below is the limiting examples about this: asthma, eczema (for example atopic dermatitis), urticaria, allergic rhinitis, anaphylaxis etc.

With the administration above-mentioned composition is the treatment of feature or the method for preventing any sufferer relevant with pain.The applicant has proposed such hypothesis: this therapeutical effect relates to immunoregulation effect, is likely anaphylactoid inhibitory action.

Therefore, the present composition is suitable for the disease for the treatment of or preventing to be caused by various tissue inflammations, for example prostatic inflammation, particularly prostatitis.

" prostatitis " is defined as the prostatic inflammatory patient's condition of influence, comprises the acute and chronic infection of specific bacteria, and more common situation is sign and the symptom that wherein has prostatitis, but can not detect specific organism.Therefore, the present composition can also be used to handle benign prostatauxe, and this is a kind of disease relevant with prostatauxe.

Astoundingly, the inventor has now found that: the therapeutic efficiency of the present composition that uses in particular for the part can be enhanced by adding Flos Inulae extract.This obtains proof in embodiment 3, the local anti-inflammatory effect that wherein contains the pharmaceutical composition of 0.1% Flos Inulae extract and 20% shea-triterpene is found the effect of the medicinal composition for part use that is better than containing 20% shea-triterpene.Therefore, the invention provides a kind of pharmaceutical composition, it comprises: the i) shea-triterpene of at least 5% (w/w); Ii) Flos Inulae extract; Optional ii) pharmaceutically suitable carrier, wherein:

The percetage by weight (w/w) of Flos Inulae extract in said composition is generally at least 0.01%, and for example at least 0.025%, at least 0.05%, at least 0.1%, at least 0.2%, at least 0.3%, or at least 0.4%, for example at least 0.5%, at least 0.75%, at least 1.0%, at least 2.5%, at least 5.0%, or at least 7.5%, at least 10.0%, for example at least 12.5%, at least 15.0%, or at least 17.5%, at least 20.0%, for example at least 25.0%, at least 30.0%, at least 35.0%, or at least 40.0%, at least 50.0%, for example at least 75.0%; In addition, the percetage by weight (w/w) of Flos Inulae extract in said composition is generally at the most 75.0%, and for example 50.0%, at the most 40.0%, for example at the most 35.0%, as at the most 30.0%, for example at the most 25.0%, for example at the most 20.0%, as at the most 10.0%, for example at the most 7.5%, as at the most 5.0%, for example at the most 2.5%, at the most 1.0%, for example at the most 0.75%, for example at the most 0.5%, for example at the most 0.4%, for example at the most 0.3%, at the most 0.2%, for example at the most 0.1%; The percetage by weight (w/w) of Flos Inulae extract in said composition can be in the 0.001-75.0% scope, such as in the 0.025-50.0% scope, such as in the 0.05-40.0% scope, for example in the 0.06-30% scope, such as in the 0.07-20% scope, such as in the 0.08-15% scope, for example in the 0.09-12% scope, for example in the 0.01-10% scope, such as in the 0.015-8% scope, such as in the 0.02-6% scope, for example in the 0.025-5% scope, such as in the 0.03-4% scope, such as in the 0.04-3% scope, for example in the 0.05-2% scope, for example in the 0.1-1% scope.Preferably, this pharmaceutical composition is used for skin or mucosa topical.

The main active of Flos Inulae extract of the present invention is a faradiol.Similar with the above-mentioned method that is used to obtain shea-triterpene, this extract can obtain by any extracting method, and this extract can extract preferred leaf or flower from any part of Flos Inulae plant.

Above mentioned pharmacotoxicological effect use for the aforesaid following treatment that is used for the local pharmaceutical composition that uses of the present invention the part principle be provided:

Treatment or prevention mammalian skin or mucosal inflammation or method hypersensitive are characterised in that described mammal administration pharmaceutical composition of the present invention.This therapeutical effect can relate to all diseases known and anaphylaxis or inflammation-related, comprises the allergy of autoimmune disease and IgE mediation.The effect of aforementioned pharmaceutical compositions of the present invention and all known sufferer and the disease association relevant with anaphylaxis below are the limiting examples about this: infect (virus, antibacterial, fungus, parasite etc.), flu and influenza, contact dermatitis, sting, the allergia nodular vasculitis, postoperative reaction, transplant rejection (graft versus host disease), asthma, eczema (for example atopic dermatitis), urticaria, allergic rhinitis, anaphylaxis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hemolytic anemia, exophthalmic goiter, myasthenia gravis, type 1 diabetes, inflammatory myopathy, multiple sclerosis, struma lymphomatosa, autoimmune adrenalitis, Crohn disease, ulcerative colitis, glomerulonephritis, progressive systemic sclerosis (scleroderma), sjogren disease, lupus erythematosus, the constitutional nodular vasculitis, rheumatoid arthritis, juvenile arthritis,juvenile chronic arthritis,juvenile rheumatoid arthritis, MCT's disease, psoriasis, pemphigus, pemphigoid, dermatitis herpetiformis etc.

According to the present invention, above-mentioned composition can combine with any other active component to strengthen therapeutical effect.

The pharmaceutically suitable carrier that is used for whole body or topical can be the water or the excipient in addition that dewaters, and described other excipient can be used for compositions and can comprise solid or liquid such as solvent, thickening agent and powder.The example separately of the excipient of these types of can be separately or using as the compositions of one or more excipient is as follows:

Emollient, such as stearyl alcohol, one castor oil acid glyceride, glyceryl monostearate, propane-1, the 2-glycol, butane-1, the 3-glycol, spermol, the isostearic acid isopropyl ester, stearic acid, the Palmic acid isobutyl ester, Standamul 7061, oleyl alcohol, isopropyl laurate, lauric acid hexyl ester, decyl oleate, octadecane-2-alcohol, different spermol, cetin, dimethyl polysiloxane, n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, Polyethylene Glycol, 2,2'-ethylenedioxybis(ethanol)., lanoline, Oleum Ricini, Acetylated lanolin alcohols., oil, mineral oil, butyl myristate, isostearic acid, Palmic acid, the linoleic acid isopropyl ester, Lauryl lactate, Tetradecyl lactate, decyl oleate, myristyl myristate;

Solvent is such as water, dichloromethane, isopropyl alcohol, Oleum Ricini, ethylene glycol monoethyl ether, DEGMBE, carbitol, dimethyl sulfoxine, oxolane, plant and animal oil, glycerol, ethanol, propanol, propylene glycol and other glycol or alcohol, expressed oi;

Wetting agent or wetting agent are such as glycerol, Sorbitol, 2-Pyrrolidone-5-carboxylic acid sodium, soluble collagen, dibutyl phthalate, gelatin;

Powder is such as Magnesiumaluminumsilicate, aluminium hydrosilicate, carboxy vinyl polymer, sodium carboxymethyl cellulose, the ethylene glycol monostearate of Chalk, Talcum, kaolin, starch and derivant thereof, natural gum, silica sol, sodium polyacrylate, chemical modification;

Gellant or bulking agent are such as pectin, gelatin and derivant thereof, cellulose derivative such as methylcellulose, carboxymethyl cellulose or oxidized cellulose, carboxymethyl cellulose, guar gum, Radix Acaciae senegalis, karaya, Tragacanth, soap clay, agar, alginate, card pool nurse, gelatin, Fucus Vesiculosus, algaroba, glucosan and derivant thereof, Ficus elastica, Strese Hofmann's hectorite., ispaghul skin, xanthan gum;

Polymer is such as polylactic acid or polyglycolic acid polymer or its copolymer, paraffin, polyethylene, polyoxyethylene, Polyethylene Glycol, polypropylene glycol, polyvinylpyrrolidone;

Surfactant, such as nonionic surfactant, for example ethylene glycol and glyceride, macrogel ether and ester, sugar ether and ester, such as sorbitan ester, ionic surfactant, such as amine soap, metallic soap, sulfated fatty alcohol, alkyl ether sulfuric acid ester, sulfonated oil, and amphoteric surfactant and lecithin (lecitins);

Buffer agent is such as sodium, potassium, aluminum, magnesium or calcium salt (such as hydrochlorate, carbonate, bicarbonate, citrate, gluconate, lactate, acetate, gluceptate or tartrate).

In addition, obviously, according to the purposes that is used for preparing medicine or food supplement of the present invention, above-mentioned composition can mix with additive such as surfactant, solvent, thickening agent, stabilizing agent, antiseptic, antioxidant, flavoring agent etc., to obtain the required finished product preparation that is suitable for whole body or topical.Similarly, medicine of the present invention or food supplement can further contain this class additive.For the route of administration of preparation or dosage form without limits, below be limiting examples: tablet, capsule, lozenge, chewing gum, liquid, granule, spray (for example aerosol), inhalant, ointment, gel, liniment, Emulsion (for example cream frost or lotion) etc. about this.Alternatively, compositions also can contain surfactant such as bile salts, polyethylene glycol oxide-sorbitan-fatty acid ester or the blended long-chain fatty acid ester of polyhydric alcohol, they can be used for improving the dispersibility of compositions in Digestive system, thereby can improve bioavailability, perhaps be used to obtain the final dosage form of compositions.

Except preparation described above, the present composition also can be mixed with depot formulation.This durative action preparation can pass through drug delivery implant (for example subcutaneous or intramuscular implant) or by the intramuscular injection administration.Therefore, for example, said composition can with suitable polymerization or hydrophobic substance (for example being mixed with the Emulsion in acceptable oil) formulated together or formulated together with ion exchange resin, perhaps be mixed with sl. sol. derivant, for example be mixed with sl. sol. salt.

On the other hand, can use the other drug delivery system.Liposome and Emulsion are the well-known examples that can be used to discharge the release vehicle of the present composition.In addition, said composition can use sustained release system to discharge, such as the semi permeability substrate of the solid polymer that contains therapeutic agent.Now determined multiple sustained-release material, and be well known to those skilled in the art.According to their chemical property, lasting release capsule can arrive continuous release composition in maximum times more than 100 days in several weeks.

In addition, the present invention relates to the aforesaid pharmaceutically active preparation of compositions method that is used for the whole body administration, be characterised in that the extract or the concentrate that obtain Butyrospermum parkii, described extract or concentrate comprise at least a following member's of being selected from triterpene alcohol: butyryl spermol, lupeol, Parker alcohol, germanicol,

Agate dienol, 24-methylene- Agate enol, α-Zhi Tansu and β-fat wingceltis element, and at least a sterol that is selected from the following member: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol, wherein said triterpene and sterol can be the forms of free alcohol or its ester, esp meat cinnamic acid, acetic acid or fatty acid ester; Alternatively described extract or concentrate are mixed with the pharmaceutically suitable carrier that is used for the whole body administration.

The specific embodiment

Embodiment 1

Research overview

With the possible anti-inflammatory activity of utilizing the assessment of collagen monoclonal antibody (mAb) and lipopolysaccharide-induced BALB/c mouse arthritis model according to Butyrospermum parkii concentrate BPC of the present invention.The test substances oral administration, once a day, successive administration 3 days.In the time of the 7th, 10,14 and 17 day, under 50mg/kg x 3 dosage, observe back podedema situation and significant minimizing (57%, 58%, 67% and 78%) is arranged with respect to the matched group of handling with excipient.Observe back podedema situation with the cyclophosphamide of 10mg/kg x 3 dosage concurrent testings the 10th, 14 and 17 day the time and reduced 79%, 91% and 90% with respect to the matched group of handling with excipient.

Test substances

Be prepared as follows the present composition:, subsequently the Butyrospermum parkii concentrate that obtains is diluted in the Semen Maydis oil with the Adeps Bovis seu Bubali resin fractional distillation.Used Butyrospermum parkii concentrate (hereinafter being called BPC) contains the shea that is selected from the following member-triterpene composition (being mainly the form of cinnamate) of 26%: butyryl spermol, lupeol, Parker alcohol, germanicol,

Agate dienol, 24-methylene-

Agate enol, α-Zhi Tansu and β-fat wingceltis element comprises the shea-triterpene of following concrete amount:

-23% lupeol;

-39% α-Zhi Tansu and β-fat wingceltis element; With

-26% butyryl spermol

This concentrate contains 2.2% the sterol that is selected from the following member in addition: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol.

Mode of administration

BPC is dissolved in 100% Semen Maydis oil.Test substances is with the 50mg/kg oral administration, and once a day, for three days on end, the 10mg/kg cyclophosphamide is as positive control, also so administration.The administration volume is 5ml/kg.

Animal

In this research, use the male BALB/c mouse of heavy 20 ± 1 grams.The space of distributing to 5 mices is 45 * 23 * 15cm.Animal is closed at APEC (NJ 08501 for AllentownGaging, Allentown, U.S.A.) in the cage, keeps clean environment, control temperature (22 ℃-24 ℃) and humidity (60%-80%) and in addition 12 hours light/dark cycle reach and use preceding at least one week.Animals can freely obtain standard laboratory mice food and tap water.The various aspects of this work comprise that the processing of raising, experiment and animal generally speaking all carries out according to " the international guideline that relates to the biomedical research of animal " (CIOMSPublication No.ISBN 92 90360194,1985).

Chemicals

In this research used chemicals be Semen Maydis oil (Sigma, U.S.A.), cyclophosphamide (Sigma, U.S.A.), lipopolysaccharide (Sigma, U.S.A.) and Arthrogen-CIA ^TMMonoclonal antibody D8, F10, DI-2G and A2 (Chondrex, U.S.A.).

Equipment

Used equipment be the plethysmometer (Ugo Basile, U.S.A.).

Method

This research is carried out according to the method (" autoimmune " 22:137-147,1995) of Terato etc.

Be used to utilize monoclonal antibody (mAbs) and lipopolysaccharide (LPS) to induce arthritis every group of 5 BALB/c mouse in age in 6-8 week.Animal in the time of the 0th day with the conjugate of 4mg/ 4 kinds of different mA bs of total amount intravenously administrable (D8, F10, DI-2G and A2) only.Follow (the 3rd day) intravenous injection 25 μ g LPS after 72 hours.Since the 3rd day, the oral administration test substances, once a day, for three days on end.In the time of the 5th day, the rubescent and swelling of 1 or 2 claws (particularly metapedes) beginning, since the 7th day, the seriously rubescent and enlargement that becomes of the arthritic symptom of two metapedes of undressed mice.In the time of the 7th, 10,14 and 17 day, measure the increase of two metapedes volumes with the plethysmometer (Ugo Basile Cat#7150) who has pond (diameter 12mm).The following calculating of inhibition percent of the sufficient volume that increases:

Suppress (%): [1-(Tn-To)/(Cn-Co)] x 100

Wherein:

Co (Cn): the volume during excipient control group mice the 0th day (n days) (two metapedes and)

To (Tn): the volume during test substances processed group mice the 0th day (n days) (two metapedes and)

Statistical procedures

Use comes the swelling situation of compare test compound treatment group and the swelling situation of matched group to matching poor Wilcoxon sum of ranks (rank sum) check.

The result

In the time of the 7th, 10,14 and 17 day, under 50mg/kg x 3 dosage, observe the back podedema and minimizing (57%, 58%, 67% and 78%) is arranged with respect to the matched group of handling with excipient.Inhibitory action in the time of the 10th, 14 and 17 day be significant on the statistics (p＜0.05, Wilcoxon).Observing back podedema situation the 10th, 14 and 17 day the time with the cyclophosphamide of 10mg/kg x 3 dosage concurrent testings has with respect to the matched group of handling with excipient and reduces (p＜0.05 on the statistics significantly, Wilcoxon), be respectively 79%, 91% and 90%.

Embodiment 2

Background

Four kinds of medicinal composition for part use of the present invention that will contain 5-20% shea-triterpene compare with the common cosmetic cream that contains the Adeps Bovis seu Bubali resin that is equivalent to 1% Butyrospermum parkii triterpene.

The purpose of this research is the pharmacotoxicological effect and the effect that contains the known compositions of Adeps Bovis seu Bubali resin that contrasts the present composition with the inductive mice inflammatory model of the active Buddhist ripple of fixed test local anti-inflammatory ester.

Method

Preparation four kinds of present compositions, the reference composition that contains Adeps Bovis seu Bubali resin and negative control compositionss on the basis of following cream frost substrate:

Hydrogenation rapeseed oil, Cremeol PS-6, Aarhus Olie, Denmark 10.0%

Sodium stearoyl lactate, Danisco Ingredients, Denmark 5.0%

The monostearate sorbitan ester, Danisco Ingredients, Denmark 3.0%

Glyceryl monostearate, Danisco Ingredients, Denmark 2.0%

Methyl hydroxybenzoate, Unichem, Denmark 0.3%

Pure water adds to 100%

The negative control compositions does not add any other additive and makes.Four kinds of pharmaceutical compositions of the present invention are prepared by adding Butyrospermum parkii concentrate (oil by the fractional distillation Adeps Bovis seu Bubali resin obtains), and the content that is equivalent to shea-triterpene respectively is 5%, 10%, 15% and 20%.The Adeps Bovis seu Bubali resin compositions of contrast makes by the Adeps Bovis seu Bubali resin that adding is equivalent to 1% shea-triterpene.

Mensuration is carried out according to the method (" European pharmacology's magazine " (1987) 142:197) of Chang etc.Ear's inflammation is induced by local application Buddhist ripple ester.Every group of 5 BALB/c mouse were carried out pretreatment and handled (post processing) after 15 minutes before using Buddhist ripple ester in 30 minutes.

Use 4 hour record swelling degree behind the Buddhist ripple ester.Every mice is with from as contrast, and an ear is handled, and the another ear is not treated.

The result

The percentage that has shown the ear enlargement in the table 1 suppresses average.Medicinal composition for part use dose dependent of the present invention ground has suppressed the ear enlargement, and the not effect of negative control and Adeps Bovis seu Bubali resin control formulation.

Table 1

Compositions	The inhibition % of ear enlargement
Compositions	The inhibition % of ear enlargement	5% shea-triterpene preparation	11
10% shea-triterpene preparation	14	5% shea-triterpene preparation	11
10% shea-triterpene preparation	14	15% shea-triterpene preparation	20
20% shea-triterpene preparation	33	15% shea-triterpene preparation	20
20% shea-triterpene preparation	33	The Adeps Bovis seu Bubali resin contrast	0
Negative control	0	The Adeps Bovis seu Bubali resin contrast	0

Explain

This research clearly illustrates that: the medicinal composition for part use of the present invention that contains at least 5% shea-triterpene has significant antiinflammatory action, and common Adeps Bovis seu Bubali resin preparation does not have antiinflammatory action.

Therefore this research proves that clearly pharmaceutical composition of the present invention is far superior to common Adeps Bovis seu Bubali resin preparation on the pharmacology.

Embodiment 3

Background

Contrast the effect of two kinds of medicinal composition for part use of the present invention with the inductive mice inflammatory model of the active Buddhist ripple of fixed test local anti-inflammatory ester, a kind of shea-triterpene of 20% that contains, another kind contain 20% shea-triterpene and 0.1% Flos Inulae extract.

Method

Two kinds of present compositions of preparation and negative control compositions on the basis of following cream frost substrate:

Hydrogenation rapeseed oil, Cremeol PS-6, Aarhus Olie, Denmark 10.0%

Sodium stearoyl lactate, Danisco Ingredients, Denmark 5.0%

The monostearate sorbitan ester, Danisco Ingredients, Denmark 3.0%

Glyceryl monostearate, Danisco Ingredients, Denmark 2.0%

Methyl hydroxybenzoate, Unichem, Denmark 0.3%

Pure water adds to 100%

The negative control compositions does not add any other additive and makes.The content that two kinds of pharmaceutical compositions of the present invention are equivalent to shea-triterpene by adding is that 20% Butyrospermum parkii concentrate (oil by the fractional distillation Adeps Bovis seu Bubali resin obtains) is prepared, wherein a kind of Flos Inulae extract (by the supercritical carbon dioxide extraction preparation) of 0.1% of also adding in addition.

The result

The percentage that has shown the ear enlargement in the table 2 suppresses average.Two kinds of medicinal composition for part use of the present invention have clearly suppressed the ear enlargement, and the not effect of negative control preparation.

Table 2

Compositions	The inhibition % of ear enlargement
Compositions	The inhibition % of ear enlargement	Shea-triterpene+Flos Inulae	50
Shea-triterpene	21	Shea-triterpene+Flos Inulae	50
Shea-triterpene	21	Negative control	0

Explain

This research clearly illustrates that: the medicinal composition for part use that contains the conjugate of shea-triterpene and Flos Inulae extract is better than only containing the compositions of shea-triterpene.

Embodiment 4

General introduction

Assess the acute oral toxicity of Butyrospermum parkii concentrate BPC of the present invention with rat.Under 2000mg/kg dosage, do not see BPC toxigenicity or mortality rate.Therefore reach a conclusion: LD ₅₀More than the 2000mg/kg body weight.

Test substances

Be prepared as follows the present composition:, subsequently the Butyrospermum parkii concentrate that obtains is diluted in the Semen Maydis oil with the Adeps Bovis seu Bubali resin fractional distillation.Used Butyrospermum parkii concentrate (hereinafter being called BPC) contains the shea that comprises following component-triterpene composition of 33%:

-26% (w/w) lupeol;

-44% (w/w) α-Zhi Tansu and/or β-fat wingceltis element; With

-30% (w/w) butyryl spermol;

This concentrate contains 2.7% the sterol composition that comprises following component in addition:

-43% hitodesterol;

-37% stigmasterol; With

-11% avenasterol.

The research explanation

The rat acute oral toxicity is according to OECD guide No 420, " acute oral toxicity-fixative is mensuration " in July, 1992, with be published in " official of European Economic Community magazine " No:L383A, the 35th volume, on December 29th, 1992, and the EEC instruction in the B1 part " acute toxicity (oral)-fixative is mensuration " is measured.

This research begins with visualization study, wherein to 1 female rats administration 2000mgBPC/kg body weight.Do not observe this rat and the clinical toxicity symptom occurs.

On visualization study result's basis, use one group of rat forming by 5 female rats to carry out main body research, every rat administration 2000mg BPC/kg body weight.

All animals in the main body research all survive and show does not have the overt toxicity symptom.

Rat has normal weight increase during studying.

Under the experiment condition described in this report, we find the dosage level (2000mg BPC/kg body weight) tested, and the highest essential dosage level does not cause death.Minimal lethal dose is more than 2000mg BPC/kg body weight.

Embodiment 5

General introduction

With the patient who suffers from rheumatoid arthritis carry out at random, the II phase clinical research of double blinding and placebo, with the safety and the usefulness of testing Butyrospermum parkii concentrate of the present invention.

Test substances

Be prepared as follows the present composition:, subsequently the Butyrospermum parkii concentrate that obtains is mixed with the Gelseal that contains the 750mg concentrate separately with the Adeps Bovis seu Bubali resin fractional distillation.Used Butyrospermum parkii concentrate (hereinafter being called BPC) contains the shea that comprises following component-triterpene composition of 33%:

-26% (w/w) lupeol;

-44% (w/w) α-Zhi Tansu and/or β-fat wingceltis element; With

-30% (w/w) butyryl spermol;

-43% hitodesterol;

-37% stigmasterol; With

-11% avenasterol.

The Cebo-Caps that preparation has identical outward appearance and weight.

Research purpose

Purpose is to test rheumatoid arthritis people administration every day 1500mg BPC, and usefulness and the safety of administration during 18 weeks made comparisons with placebo.

Research design

With two parallel group carry out at random, the research of double blinding and placebo.

The study population

40 man/female patients that are diagnosed as rheumatoid arthritis.Allow these patients to continue the Drug therapy that they exist at present.

Project

In the 1st visit, will satisfy the standard that is selected into and the patient by exclusion standard assigns in following group at random:

-BPC 750mg x 2/ day

-placebo x 2/ day

When the 1st, 2 (6 weeks), 3 (12 weeks) and 4 (18 weeks) inferior visits, use the state of Stamford health evaluating application form (HAQ) evaluating patient of generally acknowledging.

Embodiment 6

General introduction

With 15 suffer from that psoriasic patient carries out at random, the II phase clinical research of double blinding and placebo, with the safety and the usefulness of testing Butyrospermum parkii concentrate of the present invention.

Use similar research that identical pharmaceutical composition of the present invention carries out 120 patients that suffer from atopic dermatitis just in set-up procedure.

Test substances

Be prepared as follows the present composition:, subsequently the Butyrospermum parkii concentrate that obtains is formulated in the standard cream frost substrate that contains 40% concentrate with the Adeps Bovis seu Bubali resin fractional distillation.The component of cream frost substrate is: water, PEG-6 stearate, ethylene glycol stearate, PEG-32 stearate, starch, acetic acid cetyl og methyl/propyl group-p-Hydroxybenzoate.

Used Butyrospermum parkii concentrate (hereinafter being called BPC) contains the shea that comprises following component-triterpene composition of 33%:

-26% (w/w) lupeol;

-44% (w/w) α-Zhi Tansu and/or β-fat wingceltis element; With

-30% (w/w) butyryl spermol;

-43% hitodesterol;

-37% stigmasterol; With

-11% avenasterol.

The placebo cream frost (same matrix) that preparation has identical appearance.

Research purpose

Purpose is usefulness and the safety of test when psoriasis patient administered twice 40%BPC on the one cream frost was continued for 12 weeks, makes comparisons with placebo.

Research design

The left side of double blinding at random,, placebo/right side research (patient compares with self).

The study population

15 are diagnosed as psoriasic man/female patient.Allow these patients to continue the Drug therapy that they exist at present.

Project

In the 1st visit, will satisfy the standard that is selected into and the patient by exclusion standard assigns in the following treatment group (left side/right side) at random:

-BPC 40% cream frost x 2/ day

-placebo cream frost x 2/ day

When the 1st, 2 (4 weeks), 3 (8 weeks) and 4 (12 weeks) inferior visits, use the state of the PASI score-sheet evaluating patient of generally acknowledging.

Claims

1. extracts of Butyrospermum parkii or concentrate are used to prepare the purposes of the peroral dosage form for the treatment of autoimmune disease and/or inflammation disease, and wherein said peroral dosage form comprises compositions composed as follows:

-at least 5% w/w lupeol;

-at least 5% w/w α-Zhi Tansu and/or β-fat wingceltis element;

-at least 5% w/w butyryl spermol;

Wherein said lupeol, α-Zhi Tansu and/or β-fat wingceltis element and butyryl spermol are the forms of free alcohol or its ester.

2. according to the purposes of claim 1, described disease is selected from psoriasis, atopic dermatitis, contact dermatitis, Crohn disease, ulcerative colitis, rheumatoid arthritis or osteoarthritis.

3. according to the purposes of claim 2, wherein said disease is rheumatoid arthritis or osteoarthritis.

4. according to the purposes of claim 2, wherein said disease is a psoriasis.

5. according to each purposes of claim 1-4, wherein said peroral dosage form is a capsule.

6. according to each purposes of claim 1-4, wherein said compositions comprises:

-at least 8% w/w lupeol;

-at least 8% w/w α-Zhi Tansu and/or β-fat wingceltis element;

-at least 8% w/w butyryl spermol;

7. according to the purposes of claim 6, wherein said compositions comprises

-at least 10% w/w lupeol;

-at least 10% w/w α-Zhi Tansu and/or β-fat wingceltis element;

-at least 10% w/w butyryl spermol;

8. according to each purposes of claim 1-4, wherein said compositions further comprises at least a following member's of being selected from sterol: stigmasterol, avenasterol, 24-methyl-cholest-7-enol, candle fruit sterol A, candle fruit sterol B and hitodesterol, wherein said sterol is the form of free alcohol or its ester.

9. according to each purposes of claim 1-4, wherein said compositions further contains Flos Inulae extract.